CAR-T Cell Therapy in India

CAR-T Cell Therapy in India is an advanced cancer treatment that uses a patient’s own immune cells to identify and attack certain cancer cells. CAR-T stands for Chimeric Antigen Receptor T-cell therapy. It is a personalized form of immunotherapy mainly used for selected blood cancers, including certain types of leukemia and lymphoma.

India has developed advanced cellular therapy programmes and indigenous CAR-T products, making it an important destination for patients seeking specialized cancer treatment. MedIndia Tours helps international patients explore CAR-T treatment options, connect with appropriate hospitals and specialists, and coordinate their medical journey in India.

What Is CAR-T Cell Therapy?

CAR-T cell therapy is a type of cellular immunotherapy in which a patient’s T cells are collected from the blood and modified in a specialized laboratory.

The modified T cells are designed to recognize a particular protein, or antigen, present on cancer cells. After the cells are prepared, they are infused back into the patient’s body, where they can recognize and attack targeted cancer cells.

CAR-T therapy is different from conventional chemotherapy because it uses specially engineered immune cells as part of the treatment.

Which Cancers Can Be Treated With CAR-T Therapy?

CAR-T therapy is currently primarily used for selected blood cancers.

Depending on the CAR-T product and approved indication, it may be considered for:

  • B-cell acute lymphoblastic leukemia (B-ALL)
  • B-cell lymphomas
  • Diffuse large B-cell lymphoma (DLBCL)
  • Certain relapsed or refractory B-cell malignancies
  • Other selected hematological cancers

CAR-T therapy is not suitable for every cancer patient. Eligibility depends on the cancer type, stage, previous treatments, disease response, patient’s overall health and the specific CAR-T product available.

Benefits of CAR-T Cell Therapy

CAR-T therapy offers a different treatment approach for selected patients with certain blood cancers, particularly when standard treatments have not produced the desired response.

Potential advantages include:

  • Personalized cellular therapy
  • Uses the patient’s own T cells
  • Targets specific cancer antigens
  • Can provide significant responses in selected blood cancers
  • Available as an advanced treatment option at specialized Indian centres
  • Indigenous CAR-T products are available in India for approved indications

However, CAR-T therapy is a complex treatment and response cannot be guaranteed.

Why Choose India for CAR-T Cell Therapy?

India has developed specialized cancer hospitals, hematology departments and cellular therapy programmes.

Patients may benefit from:

  • Experienced oncology and hematology specialists
  • Advanced cancer diagnostic facilities
  • Specialized cellular therapy centres
  • CAR-T treatment programmes
  • Indigenous CAR-T technology
  • Bone marrow transplantation facilities
  • Multidisciplinary cancer care
  • International patient services

The availability of CAR-T therapy depends on the hospital, product, regulatory indications and patient eligibility.

Frequently Asked Questions (FAQ's)

NexCAR19 is an indigenous CAR-T cell therapy developed in India that targets the CD19 antigen on certain B cells.

The cost varies depending on the CAR-T product, hospital, investigations, hospitalization, medicines and other medical requirements. A personalized quotation is recommended.

 

The overall process can take several weeks because it includes evaluation, cell collection, manufacturing, preparation, infusion and monitoring.

 

 

The cell collection and infusion procedures are performed under medical supervision. Patients may experience side effects from conditioning therapy or CAR-T treatment, which require close monitoring.

CAR-T therapy is primarily established for selected blood cancers. Its use in solid tumors remains an area of ongoing research and development.

Recent diagnosis reports, biopsy or bone marrow reports, imaging, blood tests, previous treatment records and discharge summaries are generally useful for an initial medical review.

CAR-T therapy can cause serious side effects. These may include:

  • Cytokine Release Syndrome (CRS)
  • Fever
  • Low blood pressure
  • Low blood-cell counts
  • Infections
  • Neurological complications
  • Fatigue
  • Other treatment-related complications

Patients require close monitoring by an experienced medical team.

Selected children may be eligible for CAR-T therapy depending on their cancer type, age, disease status and the approved indication of the specific product. Pediatric patients should be evaluated by a specialized pediatric oncology or hematology team.

Scroll to Top